<DOC>
	<DOCNO>NCT02503332</DOCNO>
	<brief_summary>The primary objective study assess safety , tolerability evidence activity multiple intravitreal ( IVT ) injection APL-2 subject Geographic Atrophy associate Age-Related Macular Degeneration ( AMD ) .</brief_summary>
	<brief_title>Study APL-2 Therapy Patients Geographic Atrophy</brief_title>
	<detailed_description>This Phase II , prospective , multicenter , randomize , single-masked , sham-controlled study ass safety , tolerability evidence activity multiple IVT injection APL-2 subject GA associate Age-Related Macular Degeneration . Patients diagnose GA associate age-related macular degeneration study eye meet inclusion/exclusion criterion include study . The study randomize approximately 240 subject obtain least 200 evaluable subject across 40 multinational site . Subjects screen within 14 day receive APL-2 . Upon entry study , subject assign screen number . Patients meet inclusion exclusion criterion confirm eligible CRC return clinic randomization treatment visit 2 ( Day 0 ) . At visit , subject randomize 2:2:1:1 manner receive APL 2 Monthly ( AM ) , APL-2 Every-Other-Month ( AEOM ) , Sham injection Monthly ( SM ) Sham injection Every-Other-Month ( SEOM ) , respectively . All subject return clinical site Day 7 ass acute safety first injection . After , subject monthly group return clinical site additional APL-2 ( Sham ) injection study procedure every month Month 12 . Subjects Every-Other-Month group return clinical site additional APL-2 ( Sham ) injection study procedure every two month Month 12 . All subject return follow-up visit Months 15 18 ( 3 6 month last injection , respectively ) .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>Unless specify otherwise , ocular specific inclusion criterion apply study eye . 1 . Male Female . 2 . Age great equal 50 year . 3 . BCVA 20/320 ( Snellen equivalent ) well use ETDRS chart . 4 . Diagnosis GA macula secondary agerelated macular degeneration , confirm within 14 day prior randomization central reading center ( CRC ) use Fundus Autofluorescence ( FAF ) image , well follow criterion : 1 . Total GA area must ≥ 2.5 ≤ 17.5 mm2 ( 1 7 disk area [ DA ] respectively ) , determine screen image FAF . 2 . If GA multifocal , least one focal lesion must ≥ 1.25 mm2 ( 0.5 DA ) . 3 . GA completely visualize macula center image . 4 . GA must able photographed entirety . 5 . GA must able measure separately area peripapillary atrophy assess CRC . 6 . Presence pattern hyperautofluorescence junctional zone GA . Absence hyperautoflouorescence ( i.e . pattern = none ) exclusionary . See Holz et al . 2007.1 5 . Female subject must : 1 . Women nonchildbearing potential ( WONCBP ) , 2 . Women childbearing potential ( WOCBP ) negative pregnancy test screening must agree use protocol define method contraception duration study . 6 . Males female partner childbearing potential must agree use protocol define method contraception agree refrain donate sperm duration study . 7 . Willing able give inform consent . Unless specify otherwise , ocular specific inclusion criterion apply study eye . 1 . GA due cause AMD Stargardt disease , cone rod dystrophy toxic maculopathies like plaquenil maculopathy . 2 . Spherical equivalent refractive error demonstrate &gt; 6 diopter myopia axial length &gt; 26 mm . 3 . Any history current evidence exudative ( `` wet '' ) AMD include evidence retinal pigment epithelium rip evidence neovascularization anywhere retina base fluorescein angiogram assess CRC . 4 . Retinal disease AMD ; however , benign condition vitreous peripheral retina exclusionary ( i.e . pavingstone degeneration ) . 5 . Any ophthalmologic condition reduces clarity medium , opinion Investigator interfere ophthalmologic examination ( e.g . advanced cataract corneal abnormality ) . 6 . Any ophthalmologic condition prevents adequate image retina judge site CRC . 7 . Intraocular surgery ( include lens replacement surgery ) within 3 month prior randomization . 8 . Aphakia absence posterior capsule . Previous violation posterior capsule also exclude unless occur result yttrium aluminum garnet ( YAG ) laser posterior capsulotomy association prior posterior chamber intraocular lens implantation least 60 day prior Day 0 . 9 . Any ophthalmic condition may require surgery study period . 10 . Any contraindication IVT injection include current ocular periocular infection . 11 . History uveitis endophthalmitis . 12 . History IVT injection time . 13 . Participation another interventional clinical study , use experimental treatment AMD investigational new drug within 6 week 5 halflives active ( whichever longer ) prior start study treatment . Note : clinical trial solely involve observation , overthecounter vitamin , supplement , diet exclusionary . 14 . Medical psychiatric condition , opinion investigator , make consistent followup treatment period unlikely , general poor medical risk systemic disease active uncontrolled infection . 15 . Any screen laboratory value ( hematology , serum chemistry urinalysis ) opinion Investigator clinically significant suitable study participation . 16 . Hypersensitivity fluorescein .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>